Condition
Excessive Daytime Somnolence
Total Trials
5
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (2)
P 3 (1)
Trial Status
Completed3
Withdrawn2
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04451668Phase 3Completed
An Open Label Study of FT218 in Subjects With Narcolepsy
NCT05056194Phase 2Withdrawn
Valiloxybate (XW10172 MR) Efficacy and Safety Parkinson's Disease Study
NCT05008341Phase 1Completed
Evaluate Sunosi® PK in Breast Milk and Plasma of Healthy Postpartum Women Following Single Dose Oral Administration
NCT04049682WithdrawnPrimary
Start Times and Restful Sleep
NCT00459420Phase 2Completed
Caffeine for Excessive Daytime Somnolence in Parkinson's Disease
Showing all 5 trials